环硅酸锆钠联合肾素-血管紧张素-醛固酮系统抑制剂治疗慢性肾脏病的机制和效果的研究进展
Research progress on the mechanism and effect of Sodium Zirconium Cy-closilicate combined with renin-angiotensin-aldosterone system inhibitors in treatment of chronic kidney disease
岳佳丽 1海光 1雷卓颖 1王丽君1
作者信息
- 1. 哈尔滨医科大学基础医学院,黑龙江哈尔滨 150081
- 折叠
摘要
肾素-血管紧张素-醛固酮系统抑制剂(RAASi)能够延缓慢性肾脏病(CKD)的进展,但常因易引起高钾血症而受到限制.而新型口服钾结合剂环硅酸锆钠(SZC)与RAASi联合治疗可快速降低CKD患者血钾水平,并改善CKD患者肾功能.然而,两者联合治疗CKD的作用机制尚未完全阐明.因此,本文主要讨论SZC与RAASi在单独使用或联合使用时对CKD的作用机制及治疗效果,旨在为CKD患者提供更优化的治疗方案.
Abstract
Renin-angiotensin-aldosterone system inhibitors(RAASi)can delay the progression of chronic kidney disease(CKD),but are often limited by their susceptibility to hyperkalemia.A new oral potassium binder,Sodium Zirconium Cyclosilicate(SZC),combined with RAASi,can rapidly reduce the serum potassium level and improve kidney function in CKD patients.However,the action mechanism of the combined treatment of CKD has not been fully elucidated.Therefore,this paper mainly discusses the mechanism and therapeutic effect of SZC and RAASi on CKD when used alone or in combination,aiming to provide a more optimized treatment plan for patients with CKD.
关键词
环硅酸锆钠/肾素-血管紧张素-醛固酮系统抑制剂/慢性肾脏病/高钾血症Key words
Sodium Zirconium Cyclosilicate/Renin-angiotensin-aldosterone system inhibitors/Chronic kidney disease/Hyperkalemia引用本文复制引用
基金项目
国家自然科学基金资助项目(31971064)
黑龙江省自然科学基金项目(YQ2020C042)
出版年
2024
NETL
NSTL
万方数据